Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Mutant KRAS is a druggable target for pancreatic cancer.

Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2.

2.

Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.

Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y.

Ann Neurol. 2012 May;71(5):699-708. doi: 10.1002/ana.22694.

PMID:
22522482
3.

The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.

Nevo Y, Aga-Mizrachi S, Elmakayes E, Yanay N, Ettinger K, Elbaz M, Brunschwig Z, Dadush O, Elad-Sfadia G, Haklai R, Kloog Y, Chapman J, Reif S.

PLoS One. 2011 Mar 22;6(3):e18049. doi: 10.1371/journal.pone.0018049.

Supplemental Content

Loading ...
Support Center